Layer 02 · Finance

Finance / control room

Revenue ingestion, forecasting, AR automation and the executive view CFOs and COOs use to read the business.

Executive Dashboard · CFO / COO View Restricted role · read-only

MTD Revenue

$528.4K

+12.4%

Forecast Variance

−3.1%

vs plan

Days Sales Outstanding

47 d

−6 d

Active Patient Visits

316

+38 wow

CRIO Revenue Report

API · soon

Drop CRIO export here

or click to browse · .csv, .xlsx accepted

Step 1

Upload export

Step 2

Auto-parse

Step 3

Reconcile

Direct CRIO API connection arriving next quarter — no more manual exports.

Revenue Forecast · 6 quarters

$ in thousands

Q4 forecast

$1,612K

FY model

$4,867K

Variance to plan

+6.2%

Per-Study Revenue Forecast · per subject → study → bottom line

CRIO API · live· sync 6/18/2026, 5:48:33 PM· MOCK

Study	Indication	Active Subjects	$ / Subject	Visits Left	Q4 Forecast	FY Forecast
ONCO-241	NSCLC Stage III	19	$28,400	142	$539.6K	$812.4K	drill →
CARDIO-118	HFpEF	12	$14,600	88	$175.2K	$311.8K	drill →
NEURO-077	Early Alzheimer's	11	$21,900	104	$240.9K	$401.4K	drill →
DERM-302	Atopic Dermatitis	38	$8,400	184	$319.2K	$612.5K	drill →
GI-211	Crohn's Disease	16	$17,200	72	$275.2K	$488.0K	drill →
ENDO-156	Type 2 Diabetes	27	$11,900	156	$321.3K	$642.2K	drill →
Total · all studies		123	—	746	$1871.4K	$3268.3K

Forecast = active subjects × $/subject × remaining visits (per study SOW) · source: /api/crio/forecastClick row to drill into study →

Studies

5 active+awarded

Gross potential

$2.91M

all studies

Probability-wtd

$2.78M

risk-adjusted

Top study P-Wtd

$859K

ONCO-241

Top 5 by P-Wtd revenueManage

Protocol	TA · Phase	Status	P(award)	Gross	P-Wtd
ONCO-241 Pembrolizumab Combo · Adv NSCLC	Oncology · Ph III	Active	100%	$859K	$859K
DERM-302 Topical JAKi · Atopic Dermatitis	Dermatology · Ph III	Awarded	100%	$541K	$541K
NEURO-077 Anti-Tau · Early Alzheimer's	Neurology · Ph II	Active	100%	$412K	$412K
CARDIO-118 Heart Failure Antifibrotic · HFrEF	Cardiology · Ph II	Active	100%	$376K	$376K
ENDO-156 GLP-1 RA · Type 2 Diabetes maintenance	Endocrinology · Ph IV	Active	100%	$332K	$332K

Invoice-Ready Events · 8

Total billable$21,800

Exports ·ERP push ·

Event	Study	Visit	Amount	SOW	Validated
EV-4421	ONCO-241	Cycle 4 Day 1	$4,280	ONCO-SOW-v3.1	ok
EV-4422	ONCO-241	Cycle 3 Day 1	$4,280	ONCO-SOW-v3.1	ok
EV-4423	DERM-302	Week 12	$2,105	DERM-SOW-v2.0	ok
EV-4424	GI-211	Week 4	$1,980	GI-SOW-v1.2	ok
EV-4425	ENDO-156	Baseline	$1,320	ENDO-SOW-v1.0	ok
EV-4426	ONCO-241	Cycle 2 Day 1	$4,280	ONCO-SOW-v3.1	ok
EV-4427	DERM-302	Week 16	$2,105	DERM-SOW-v2.0	review
EV-4428	CARDIO-118	Screening	$1,450	CARDIO-SOW-v1.0	review

Draft Invoices · 5

DRAFT-2025-Q4-001
Pfizer · ONCO-241
12 events · ONCO-SOW-v3.1
$51,360
Invoiced
DRAFT-2025-Q4-002
Lilly · DERM-302
22 events · DERM-SOW-v2.0
$46,310
Invoiced
DRAFT-2025-Q4-003
BMS · GI-211
7 events · GI-SOW-v1.2
$13,860
Pending
DRAFT-2025-Q4-004
Lilly · ENDO-156
14 events · ENDO-SOW-v1.0
$18,480
Invoiced
DRAFT-2025-Q4-005
AstraZeneca · CARDIO-118
8 events · CARDIO-SOW-v1.0
$11,600
Pending

Invoicing & AR Automation

0-30 days

$184,500

28 inv.

31-60 days

$92,300

14 inv.

61-90 days

$41,800

7 inv.

90+ days

$18,600

3 inv.

Downloadable Reports

5 files

PDF
Q3 2025 Revenue Recognition
Controller · 1.2 MB · 2025-10-02
XLSX
Monthly AR Aging — Sep
Controller · 284 KB · 2025-09-30
PDF
Site Productivity Snapshot
Recruitment Lead · 768 KB · 2025-09-28
XLSX
Per-Visit Margin Breakdown
Controller · 512 KB · 2025-09-25
PDF
Cash Flow Forecast — Q4
CFO · 1.8 MB · 2025-09-22

Controller note · Sep 28

"Q3 close on track. CRIO reconciliation closed within 4-day window; per-visit margins held above 38% in oncology."

— J. Liang, Controller

Recruitment lead note · Sep 30

"Funnel conversion improved 4pt MoM. CARDIO-118 remains at-risk pending an additional sub-I onboarding by Oct 15."

— M. Diaz, Recruitment Lead

CFO action item

Approve Q4 reforecast (+6.2% to plan) and authorize collection sweep on 90+ day bucket — $18.6K across 3 invoices.